#5-03E. Redefining Lupus Care: The 2026 BSR Guidelines for SLE Management (Rheumatology, 2026)

Are you struggling to balance effective disease control with the long-term risks of glucocorticoid toxicity in your systemic lupus erythematosus (SLE) patients? Today, we explore the 2026 British Society for Rheumatology (BSR) guideline, a comprehensive life-course report encompassing 102 recommendations that span from non-pharmacological interventions to advanced organ-specific therapies for both pediatric and adult SLE populations. The most pivotal clinical update is the paradigm shift in lupus nephritis induction therapy; rather than relying on mycophenolate mofetil monotherapy, the guidelines now strongly recommend early combination regimens integrating newer agents like obinutuzumab, voclosporin, or belimumab as first-line treatments. While this marks a significant advancement in minimizing steroid exposure and optimizing early immunosuppression, a critical limitation is that direct evidence for pediatric patients remains scarce, heavily necessitating the extrapolation of adult trial data. For practicing clinicians, this paper is highly relevant as it provides an actionable roadmap to confidently implement these novel biological therapies, ultimately transforming daily practice by prioritizing steroid-sparing strategies, improving long-term renal outcomes, and standardizing multidisciplinary care across the entire life course of SLE patients.

Citation: Md Yuzaiful Md Yusof, Eve M.D. Smith, et al. The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus. Rheumatology. 2026. DOI: 10.1093/rheumatology/keag223

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.